thalidomide and Blood Clot studies

Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.

Research Excerpts

Excerpt	Relevance	Reference
"A previous interim report of MM-011, the first study that combined lenalidomide with anthracycline-based chemotherapy followed by lenalidomide maintenance for relapsed and/or refractory multiple myeloma (RRMM), showed promising safety and activity."	9.19	Mature results of MM-011: a phase I/II trial of liposomal doxorubicin, vincristine, dexamethasone, and lenalidomide combination therapy followed by lenalidomide maintenance for relapsed/refractory multiple myeloma. ( Andresen, S; Ann Karam, M; Baz, R; Bruening, K; Dean, R; Faiman, B; Habecker, B; Hamilton, K; Hussein, MA; Kalaycio, M; Knight, R; Lazaryan, A; Reed, J; Reu, FJ; Sobecks, R; Srkalovic, G; Sweetenham, JW; Waksman, J; Zeldis, JB, 2014)
"Venous thromboembolism (VTE) is a major complication of myeloma therapy recently observed with the increasing use of up-front thalidomide and dexamethasone (thal-dex)."	9.14	Thalidomide-dexamethasone as up-front therapy for patients with newly diagnosed multiple myeloma: thrombophilic alterations, thrombotic complications, and thromboprophylaxis with low-dose warfarin. ( Catalano, L; Cavo, M; Cini, M; Gozzetti, A; Legnani, C; Masini, L; Palareti, G; Patriarca, F; Tacchetti, P; Tosi, P; Valdré, L; Zamagni, E, 2010)
"Lenalidomide, a derivate of thalidomide, has recently been approved in Europe for the treatment of patients with multiple myeloma."	8.84	Pathophysiological considerations to thrombophilia in the treatment of multiple myeloma with thalidomide and derivates. ( Gieseler, F, 2008)
" The risk of VTE is higher in multiple myeloma (MM) patients who receive thalidomide or lenalidomide, especially in combination with dexamethasone or chemotherapy."	8.84	Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. ( Anderson, KC; Attal, M; Barlogie, B; Belch, A; Bladé, J; Boccadoro, M; Bringhen, S; Cavo, M; Dimopoulos, MA; Durie, BG; Harousseau, J; Hussein, MA; Joshua, D; Knop, S; Kyle, R; Lonial, S; Ludwig, H; Morgan, GJ; Niesvizky, R; Orlowski, RZ; Palumbo, A; Rajkumar, SV; Richardson, PG; San Miguel, J; Sezer, O; Shimizu, K; Sonneveld, P; Vesole, D; von Lilienfeld-Toal, M; Waage, A; Weber, D; Westin, J; Zangari, M; Zonder, JA, 2008)
"To assess thromboprophylaxis prescribing patterns against current guidelines and report thromboembolism (TE) incidence in multiple myeloma (MM) patients treated with thalidomide (thal) or lenalidomide (len) at a specialist cancer hospital over a one-year period."	7.79	Thromboprophylaxis prescribing and thrombotic event rates in multiple myeloma patients treated with lenalidomide or thalidomide at a specialist cancer hospital. ( Alexander, M; Kirsa, S; Lingaratnam, S; Mellor, JD; Teoh, KC, 2013)
"Treatment with thalidomide is associated with vascular thrombosis."	7.79	Increased PAC-1 expression among patients with multiple myeloma on concurrent thalidomide and warfarin. ( Abdullah, D; Abdullah, WZ; Hussin, A; Roshan, TM; Zain, WS, 2013)
"Venous thrombosis is a well-recognized complication of lenalidomide therapy in patients with multiple myeloma, but its occurrence during the treatment of other hematologic malignancies is less well described."	7.74	Thrombosis of the corpora cavernosa complicating lenalidomide therapy of myelofibrosis. ( Carwile, J; El Rassi, FA; Tam, CS; Verstovsek, S, 2008)
"Among 199 patients treated with thalidomide for multiple myeloma, four thromboses occurred in 49 cases during erythropoietin therapy (prevalence 8."	7.72	Recombinant human erythropoietin and the risk of thrombosis in patients receiving thalidomide for multiple myeloma. ( Barbui, T; Comotti, B; Crippa, C; Elice, F; Galli, M; Rodeghiero, F, 2004)
"Five patients including 4 patients with lupus erythematosus (1 discoid lupus, 1 subacute lupus and 2 systemic lupus erythematosus) and one patient with a severe atopic dermatitis, all without previous history of vascular events, developed an arterial thrombosis (2 cases) or a venous thrombosis (3 cases), severe in 4 cases, few days or weeks after the onset of thalidomide treatment (50 to 100 mg daily)."	7.70	[Thalidomide and thrombosis]. ( Bachelez, H; Carsuzaa, F; Cavelier-Balloy, B; Dubertret, L; Flageul, B; Wallach, D, 2000)
"In patients with advanced hepatocellular carcinoma (HCC), inferior vena cava/intra-right atrial (IVC/RA) tumor thrombi are not uncommon findings and are usually associated with extremely poor outcome."	6.42	Hepatocellular carcinoma with intra-atrial tumor thrombi. A report of three cases responsive to thalidomide treatment and literature review. ( Chang, JY; Chao, TY; Chen, LT; Chuang, TR; Ka, WS; Liu, TW, 2004)
"The occurrence of a left atrial thrombus without a haemodynamic predisposing factor (arrhythmia, mitral valvulopathy, severe left ventricular dysfunction) is a rare event."	6.42	[Left atrial thrombus in multiple myeloma treated with thalidomide]. ( Barbou, F; Bonal, J; Bouchiat, C; Cellarier, G; de Jaureguiberry, JP; Dussarat, GV; Gisserot, O; Jégo, C; Landais, C; Laurent, P, 2003)
"Thalidomide is an antiangiogenic drug used in cancer therapy."	5.35	Arterial thrombosis and thalidomide. ( Cakir, O; Eren, MN; Goz, M, 2008)
"Thalidomide has been associated with venous thrombotic events, as reported in the post-marketing surveillance reports by Celgene Corporation; as well as case reports in the literature."	5.33	Arterial thrombosis in four patients treated with thalidomide. ( Brown, K; Chanan-Khan, A; Hahn, T; McCarthy, PL; Paplham, P; Roy, H; Scarpace, SL; van Besien, K, 2005)
" Aspirin or heparin was recommended for patients at high thrombosis risk."	5.20	Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance). ( Bartlett, NL; Blum, KA; Cheson, BD; Czuczman, M; Giguere, JK; Johnson, J; Jung, SH; Leonard, JP; Pitcher, BN, 2015)
"A previous interim report of MM-011, the first study that combined lenalidomide with anthracycline-based chemotherapy followed by lenalidomide maintenance for relapsed and/or refractory multiple myeloma (RRMM), showed promising safety and activity."	5.19	Mature results of MM-011: a phase I/II trial of liposomal doxorubicin, vincristine, dexamethasone, and lenalidomide combination therapy followed by lenalidomide maintenance for relapsed/refractory multiple myeloma. ( Andresen, S; Ann Karam, M; Baz, R; Bruening, K; Dean, R; Faiman, B; Habecker, B; Hamilton, K; Hussein, MA; Kalaycio, M; Knight, R; Lazaryan, A; Reed, J; Reu, FJ; Sobecks, R; Srkalovic, G; Sweetenham, JW; Waksman, J; Zeldis, JB, 2014)
"Venous thromboembolism (VTE) is a major complication of myeloma therapy recently observed with the increasing use of up-front thalidomide and dexamethasone (thal-dex)."	5.14	Thalidomide-dexamethasone as up-front therapy for patients with newly diagnosed multiple myeloma: thrombophilic alterations, thrombotic complications, and thromboprophylaxis with low-dose warfarin. ( Catalano, L; Cavo, M; Cini, M; Gozzetti, A; Legnani, C; Masini, L; Palareti, G; Patriarca, F; Tacchetti, P; Tosi, P; Valdré, L; Zamagni, E, 2010)
"With the introduction of thalidomide and multi-agent chemotherapy in the treatment of multiple myeloma around 15years ago a strongly increased risk of venous thrombosis was observed."	4.93	Update of thrombosis in multiple myeloma. ( Leebeek, FW, 2016)
"Thrombosis is a frequent feature in individuals with myeloma, particularly those treated with oral immunomodulatory drugs (IMID) such as thalidomide or lenalidomide concomitantly with anthracyclines or dexamethasone."	4.88	Thrombosis in multiple myeloma (MM). ( Braggio, E; Cesarman-Maus, G; Fonseca, R, 2012)
"Although the increased risk of venous thrombotic events with thalidomide in multiple myeloma (MM) has been well described, an association with an increased risk of arterial events is less well appreciated."	4.85	Arterial thrombosis with immunomodulatory derivatives in the treatment of multiple myeloma: a single-center case series and review of the literature. ( Martin, MG; Vij, R, 2009)
"Lenalidomide, a derivate of thalidomide, has recently been approved in Europe for the treatment of patients with multiple myeloma."	4.84	Pathophysiological considerations to thrombophilia in the treatment of multiple myeloma with thalidomide and derivates. ( Gieseler, F, 2008)
" The risk of VTE is higher in multiple myeloma (MM) patients who receive thalidomide or lenalidomide, especially in combination with dexamethasone or chemotherapy."	4.84	Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. ( Anderson, KC; Attal, M; Barlogie, B; Belch, A; Bladé, J; Boccadoro, M; Bringhen, S; Cavo, M; Dimopoulos, MA; Durie, BG; Harousseau, J; Hussein, MA; Joshua, D; Knop, S; Kyle, R; Lonial, S; Ludwig, H; Morgan, GJ; Niesvizky, R; Orlowski, RZ; Palumbo, A; Rajkumar, SV; Richardson, PG; San Miguel, J; Sezer, O; Shimizu, K; Sonneveld, P; Vesole, D; von Lilienfeld-Toal, M; Waage, A; Weber, D; Westin, J; Zangari, M; Zonder, JA, 2008)
" The level of plasma TM and D-Dimer can be elevated when thalidomide used, which indirectly suggested the tendency for thrombosis in MM patients."	3.81	[Hypercoagulable state in patients with multiple myeloma]. ( Gao, N; Liu, ZY; Lu, H; Sun, JR; Wang, XX; Yu, WZ; Zhang, GQ, 2015)
" Established risk factors in IBD colitis inpatients with TE included: indwelling catheter (4/10), first-degree family member with TE (2/10), hereditary thrombophilia (3/10), smoking (1/10), oral contraceptive (1/5 females), and thalidomide (1/10)."	3.79	Risk factors, morbidity, and treatment of thrombosis in children and young adults with active inflammatory bowel disease. ( Atkinson, BJ; Bousvaros, A; Harney, KM; Levine, AE; Lightdale, JR; Trenor, CC; Verhave, M; Zitomersky, NL, 2013)
"Treatment with thalidomide is associated with vascular thrombosis."	3.79	Increased PAC-1 expression among patients with multiple myeloma on concurrent thalidomide and warfarin. ( Abdullah, D; Abdullah, WZ; Hussin, A; Roshan, TM; Zain, WS, 2013)
"To assess thromboprophylaxis prescribing patterns against current guidelines and report thromboembolism (TE) incidence in multiple myeloma (MM) patients treated with thalidomide (thal) or lenalidomide (len) at a specialist cancer hospital over a one-year period."	3.79	Thromboprophylaxis prescribing and thrombotic event rates in multiple myeloma patients treated with lenalidomide or thalidomide at a specialist cancer hospital. ( Alexander, M; Kirsa, S; Lingaratnam, S; Mellor, JD; Teoh, KC, 2013)
"Multiple myeloma (MM) patients have a propensity for thromboembolic events (TE), and treatment with thalidomide/dexamethasone or lenalidomide/dexamethasone increases this risk."	3.74	Prophylactic low-dose aspirin is effective antithrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma. ( Christos, P; Coleman, M; De Sancho, M; Furst, J; Jalbrzikowski, J; Jayabalan, D; Leonard, J; Mark, T; Martínez-Baños, D; Mazumdar, M; Niesvizky, R; Pearse, R; Pekle, K; Zafar, F, 2007)
"Venous thrombosis is a well-recognized complication of lenalidomide therapy in patients with multiple myeloma, but its occurrence during the treatment of other hematologic malignancies is less well described."	3.74	Thrombosis of the corpora cavernosa complicating lenalidomide therapy of myelofibrosis. ( Carwile, J; El Rassi, FA; Tam, CS; Verstovsek, S, 2008)
" This patient developed acute, multiple cerebral infarctions 5 months into the treatment with thalidomide."	3.73	Should we screen patients for inherited thrombophilia before starting thalidomide? ( El-Hajj, II; Harb, MI; Mahfouz, RA; Otrock, ZK; Sawaya, RA, 2006)
"Among 199 patients treated with thalidomide for multiple myeloma, four thromboses occurred in 49 cases during erythropoietin therapy (prevalence 8."	3.72	Recombinant human erythropoietin and the risk of thrombosis in patients receiving thalidomide for multiple myeloma. ( Barbui, T; Comotti, B; Crippa, C; Elice, F; Galli, M; Rodeghiero, F, 2004)
"Five patients including 4 patients with lupus erythematosus (1 discoid lupus, 1 subacute lupus and 2 systemic lupus erythematosus) and one patient with a severe atopic dermatitis, all without previous history of vascular events, developed an arterial thrombosis (2 cases) or a venous thrombosis (3 cases), severe in 4 cases, few days or weeks after the onset of thalidomide treatment (50 to 100 mg daily)."	3.70	[Thalidomide and thrombosis]. ( Bachelez, H; Carsuzaa, F; Cavelier-Balloy, B; Dubertret, L; Flageul, B; Wallach, D, 2000)
"Thrombosis was not associated with inferior progression-free survival (PFS) or overall survival (OS), apart from inferior OS for patients with arterial events (aHR, 1."	2.94	Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials. ( Bradbury, CA; Cairns, DA; Child, JA; Cook, G; Craig, Z; Davies, FE; Drayson, MT; Gregory, WM; Hockaday, A; Jackson, GH; Jenner, MW; Jones, JR; Kaiser, MF; Morgan, GJ; Owen, RG; Paterson, A; Pawlyn, C, 2020)
"Thalidomide was associated with an increased risk of having a thrombotic event, mainly pulmonary embolus and deep vein thrombosis (19% thalidomide vs 10% placebo; HR = 2."	2.74	Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial. ( Ali, K; Ferry, D; Hackshaw, A; James, L; Jitlal, M; Lee, SM; Middleton, G; O'Brien, M; Rudd, R; Spiro, S; Woll, PJ, 2009)
"Patients with multiple myeloma (MM) are at an increased risk of venous and arterial thrombosis."	2.47	[Thrombotic complications following the treatment of multiple myeloma with new agents]. ( Gil, L; Komarnicki, M; Rupa-Matysek, J, 2011)
"The risk for venous thromboembolism is high when patients are treated with thalidomide or lenalidomide in combination with dexamethasone or multi-agent chemotherapy."	2.46	Thrombosis in multiple myeloma. ( Kristinsson, SY, 2010)
"Thalidomide has several mechanisms of action: several immuno-modulatory properties, an anti-angiogenic action and a hypnosedative effect."	2.43	[The revival of thalidomide: an old drug with new indications]. ( Laffitte, E, 2006)
"The occurrence of a left atrial thrombus without a haemodynamic predisposing factor (arrhythmia, mitral valvulopathy, severe left ventricular dysfunction) is a rare event."	2.42	[Left atrial thrombus in multiple myeloma treated with thalidomide]. ( Barbou, F; Bonal, J; Bouchiat, C; Cellarier, G; de Jaureguiberry, JP; Dussarat, GV; Gisserot, O; Jégo, C; Landais, C; Laurent, P, 2003)
"In patients with advanced hepatocellular carcinoma (HCC), inferior vena cava/intra-right atrial (IVC/RA) tumor thrombi are not uncommon findings and are usually associated with extremely poor outcome."	2.42	Hepatocellular carcinoma with intra-atrial tumor thrombi. A report of three cases responsive to thalidomide treatment and literature review. ( Chang, JY; Chao, TY; Chen, LT; Chuang, TR; Ka, WS; Liu, TW, 2004)
"Thalidomide has immunomodulatory and anti-angiogenic properties which may underlie its activity in cancer."	2.41	Thalidomide in cancer. ( Mehta, J; Singhal, S, 2002)
" The patient was administered an increasing dosage of thalidomide, up to 300 mg/day, with thromboembolism prophylaxis for 3 months, with no clinical response."	1.39	[High-dose thalidomide for severe idiopathic obscure gastrointestinal bleeding in a patient at high-thrombotic risk]. ( Gonzalez-Santiago, JM; Martín-Noguerol, E; Martinez-Alcalá, C; Molina-Infante, J; Vara-Brenes, D, 2013)
"Among hematologic malignancies, multiple myeloma (MM) confers a high risk of developing such complications, with a VTE rate of nearly 10%."	1.37	Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis. ( Brioli, A; Cavo, M; Pantani, L; Tacchetti, P; Zamagni, E; Zannetti, B, 2011)
"Thalidomide is an antiangiogenic drug used in cancer therapy."	1.35	Arterial thrombosis and thalidomide. ( Cakir, O; Eren, MN; Goz, M, 2008)
"Thalidomide has been associated with venous thrombotic events, as reported in the post-marketing surveillance reports by Celgene Corporation; as well as case reports in the literature."	1.33	Arterial thrombosis in four patients treated with thalidomide. ( Brown, K; Chanan-Khan, A; Hahn, T; McCarthy, PL; Paplham, P; Roy, H; Scarpace, SL; van Besien, K, 2005)
"Thalidomide was begun at 50 mg, p."	1.33	Assessing the ability of the antiangiogenic and anticytokine agent thalidomide to modulate radiation-induced lung injury. ( Anscher, MS; Clough, R; Crawford, J; Dewhirst, MW; Dunphy, F; Garst, J; Herndon, JE; Larrier, N; Marino, C; Marks, LB; Shafman, TD; Vujaskovic, Z; Zhou, S, 2006)

Research

Studies (55)

Authors

Clinical Trials (10)

Trial Overview

Trial Outcomes

Overall Response Rate

Timeframe	Studies, this research(%)	All Research%
pre-1990	1 (1.82)	18.7374
1990's	0 (0.00)	18.2507
2000's	34 (61.82)	29.6817
2010's	19 (34.55)	24.3611
2020's	1 (1.82)	2.80

Authors	Studies
Bradbury, CA	1
Craig, Z	1
Cook, G	1
Pawlyn, C	1
Cairns, DA	1
Hockaday, A	1
Paterson, A	1
Jenner, MW	1
Jones, JR	1
Drayson, MT	1
Owen, RG	1
Kaiser, MF	1
Gregory, WM	1
Davies, FE	1
Child, JA	1
Morgan, GJ	2
Jackson, GH	1
Ayyalu, TK	1
Issa, M	1
Zitomersky, NL	1
Levine, AE	1
Atkinson, BJ	1
Harney, KM	1
Verhave, M	1
Bousvaros, A	1
Lightdale, JR	1
Trenor, CC	1
Abdullah, WZ	1
Roshan, TM	1
Hussin, A	1
Zain, WS	1
Abdullah, D	1
Lazaryan, A	1
Hussein, MA	3
Reu, FJ	1
Faiman, B	1
Habecker, B	1
Ann Karam, M	1
Reed, J	1
Hamilton, K	1
Waksman, J	1
Bruening, K	1
Srkalovic, G	1
Andresen, S	1
Kalaycio, M	1
Sweetenham, JW	1
Sobecks, R	1
Dean, R	1
Knight, R	1
Zeldis, JB	1
Baz, R	1
Liu, ZY	1
Zhang, GQ	1
Yu, WZ	1
Wang, XX	1
Sun, JR	1
Gao, N	1
Lu, H	1
Leonard, JP	1
Jung, SH	1
Johnson, J	1
Pitcher, BN	1
Bartlett, NL	1
Blum, KA	1
Czuczman, M	1
Giguere, JK	1
Cheson, BD	1
Leebeek, FW	2
Chalayer, E	1
Chapelle, C	1
Leleu, X	1
Elalamy, I	1
Laporte, S	1
Tardy, B	1
Li, W	1
Garcia, D	1
Cornell, RF	1
Gailani, D	1
Laubach, J	1
Maglio, ME	1
Richardson, PG	2
Moslehi, J	1
Gieseler, F	1
Paydas, S	1
Niesvizky, R	4
Martínez-Baños, DM	1
Daher, IN	1
Yeh, ET	1
Mark, T	2
Coleman, M	2
Eby, C	1
Lee, SM	1
Woll, PJ	1
Rudd, R	1
Ferry, D	1
O'Brien, M	1
Middleton, G	1
Spiro, S	1
James, L	1
Ali, K	1
Jitlal, M	1
Hackshaw, A	1
Martin, MG	1
Vij, R	1
Tai, YT	1
Yen, PC	1
Chen, HH	1
Chou, EK	1
Cini, M	1
Zamagni, E	2
Valdré, L	1
Palareti, G	1
Patriarca, F	1
Tacchetti, P	2
Legnani, C	1
Catalano, L	1
Masini, L	1
Tosi, P	1
Gozzetti, A	1
Cavo, M	3
Libourel, EJ	1
Sonneveld, P	2
van der Holt, B	1
de Maat, MP	1
Kristinsson, SY	1
Brioli, A	1
Zannetti, B	1
Pantani, L	1
Rupa-Matysek, J	1
Gil, L	1
Komarnicki, M	1
Cesarman-Maus, G	1
Braggio, E	1
Fonseca, R	1
Martín-Noguerol, E	1
Martinez-Alcalá, C	1
Gonzalez-Santiago, JM	1
Vara-Brenes, D	1
Molina-Infante, J	1
Alexander, M	1
Teoh, KC	1
Lingaratnam, S	1
Kirsa, S	1
Mellor, JD	1
Moore, TJ	1
Bennett, CL	1
Francès, C	2
Barete, S	1
Ayoub, N	1
Piette, JC	2
Barbui, T	2
Falanga, A	1
Rodeghiero, F	2
Elice, F	3
Jégo, C	1
Barbou, F	1
Laurent, P	1
Gisserot, O	1
Cellarier, G	1
Bonal, J	1
Bouchiat, C	1
Landais, C	1
de Jaureguiberry, JP	1
Dussarat, GV	1
Potenza, L	1
Luppi, M	1
Morselli, M	1
Saviola, A	1
Ferrari, A	1
Riva, G	1
Longo, G	1
Marietta, M	1
Torelli, G	1
Galli, M	1
Crippa, C	1
Comotti, B	1
Chang, JY	1
Ka, WS	1
Chao, TY	1
Liu, TW	1
Chuang, TR	1
Chen, LT	1
Scarpace, SL	1
Hahn, T	1
Roy, H	1
Brown, K	1
Paplham, P	1
Chanan-Khan, A	1
van Besien, K	1
McCarthy, PL	1
Mehta, P	2
Otrock, ZK	1
Mahfouz, RA	1
El-Hajj, II	1
Harb, MI	1
Sawaya, RA	1
Zonder, JA	2
Barlogie, B	2
Durie, BG	2
McCoy, J	1
Crowley, J	1
Anscher, MS	1
Garst, J	1
Marks, LB	1
Larrier, N	1
Dunphy, F	1
Herndon, JE	1
Clough, R	1
Marino, C	1
Vujaskovic, Z	1
Zhou, S	1
Dewhirst, MW	1
Shafman, TD	1
Crawford, J	1
Zappasodi, P	1
Mangiacavalli, S	1
Terulla, V	1
Airò, F	1
Klersy, C	1
Varettoni, M	1
Corso, A	1
Hönemann, D	1
Prince, HM	1
Laffitte, E	1
Zangari, M	3
Fink, L	2
Tricot, G	1
Goz, M	1
Eren, MN	1
Cakir, O	1
El Rassi, FA	1
Tam, CS	1
Carwile, J	1
Verstovsek, S	1
Martínez-Baños, D	1
Jalbrzikowski, J	1
Christos, P	1
Furst, J	1
De Sancho, M	1
Pearse, R	1
Mazumdar, M	1
Zafar, F	1
Pekle, K	1
Leonard, J	1
Jayabalan, D	1
Palumbo, A	1
Rajkumar, SV	1
Dimopoulos, MA	1
San Miguel, J	1
Harousseau, J	1
Attal, M	1
Belch, A	1
Knop, S	1
Joshua, D	1
Sezer, O	1
Ludwig, H	1
Vesole, D	1
Bladé, J	1
Kyle, R	1
Westin, J	1
Weber, D	1
Bringhen, S	1
Waage, A	1
von Lilienfeld-Toal, M	1
Lonial, S	1
Orlowski, RZ	1
Shimizu, K	1
Anderson, KC	1
Boccadoro, M	1
Flageul, B	1
Wallach, D	1
Cavelier-Balloy, B	1
Bachelez, H	1
Carsuzaa, F	1
Dubertret, L	1
Pouaha, J	1
Martin, S	1
Trechot, P	1
Truchetet, F	1
Barbaud, A	1
Schmutz, JL	1
Camba, L	1
Peccatori, J	1
Pescarollo, A	1
Tresoldi, M	1
Corradini, P	1
Bregni, M	1
Singhal, S	1
Mehta, J	1
Sbai, A	1
Kaushal, V	1
Kohli, M	1
Petter, C	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Phase I Study of DVd +/ CC-5013 in Relapsed Refractory Multiple Myeloma (MM)[NCT00091624]	Phase 1	77 participants (Actual)	Interventional	2003-03-31	Completed
A Randomized Phase II Trial of Rituximab Versus Lenalidomide (REVLIMID™, Cc-5013) (IND#73034) Versus Rituximab + Lenalidomide in Recurrent Follicular Non-Hodgkin Lymphoma (NHL) That is Not Rituximab-Refractory[NCT00238238]	Phase 2	97 participants (Actual)	Interventional	2006-03-31	Completed
Phase Ib Dose Finding Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma (MCL)[NCT02446236]	Phase 1	27 participants (Actual)	Interventional	2015-06-18	Active, not recruiting
An Observational Study of Cardiovascular Complications of Carfilzomib Treatment in Clinical Practice[NCT03543579]		46 participants (Anticipated)	Observational	2017-03-23	Active, not recruiting
Phase I Study of Carfilzomib-based Chemotherapy Mobilization for Autologous Stem Cell Transplantation in Multiple Myeloma[NCT03909412]	Phase 1	18 participants (Anticipated)	Interventional	2019-10-08	Recruiting
A Phase III Randomized, Double Blind, Placebo Controlled Trial Of Carboplatin/Etoposide With Or Without Thalidomide In Small Cell Lung Cancer (Study 12)[NCT00061919]	Phase 3	724 participants (Actual)	Interventional	2003-04-30	Completed
Evaluation of the Use of an Oral Direct Anti-Xa Anticoagulant, Apixaban, in Prevention of Venous Thromboembolic Disease in Patients Treated With IMiDs During Myeloma : a Pilot Study[NCT02066454]	Phase 3	105 participants (Anticipated)	Interventional	2014-04-30	Recruiting
Rivaroxaban for Improvement of Thromboembolism Outcomes in Patients With Multiple Myeloma on Lenalidomide-based Therapy: RithMM Trial[NCT03428373]	Phase 2/Phase 3	86 participants (Anticipated)	Interventional	2023-07-30	Recruiting
An Open Label, Multicenter, Phase 2, Pilot Study, Evaluating Early Treatment With Bispecific T-cell Redirectors (Teclistamab and Talquetamab) in the Frontline Therapy of Newly Diagnosed High-risk Multiple Myeloma[NCT05849610]	Phase 2	30 participants (Anticipated)	Interventional	2023-11-30	Recruiting
A Phase I/II Study of Bendamustine, Lenalidomide and Low-dose Dexamethasone, (BdL) for the Treatment of Patients With Relapsed Myeloma.[NCT01686386]	Phase 1/Phase 2	60 participants (Anticipated)	Interventional	2010-02-28	Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Response is assessed by investigator according to International Working Group (IWG) criteria. A complete response requires disappearance of all evidence of disease. A partial response is a >/= 50% decrease in the sum of products of 6 largest dominant nodes or nodal masses as well as for splenic and hepatic nodules. No increase in size of nodes, liver or spleen and no new sites of disease. (NCT00238238)
Timeframe: Duration of treatment (12 cycles)

Time to Progression

Intervention	percentage of participants (Number)
Arm II - Lenalidomide	53.3
Arm III - Lenalidomide and Rituximab	76.1

Time to progression (TTP) is defined as the time from study entry until progression or death without progression. The median TTP with 95% CI was estimated using the Kaplan-Meier method. (NCT00238238)
Timeframe: Up to 10 years

Article	Year
Update of thrombosis in multiple myeloma. Thrombosis research, 2016, Volume: 140 Suppl 1 Topics: Anticoagulants; Antineoplastic Agents; Aspirin; Heparin, Low-Molecular-Weight; Humans; Lenalidomide;	2016
Cardiovascular and Thrombotic Complications of Novel Multiple Myeloma Therapies: A Review. JAMA oncology, 2017, Jul-01, Volume: 3, Issue:7 Topics: Antineoplastic Agents; Cardiovascular Diseases; Humans; Immunologic Factors; Lenalidomide; Multiple	2017
Pathophysiological considerations to thrombophilia in the treatment of multiple myeloma with thalidomide and derivates. Thrombosis and haemostasis, 2008, Volume: 99, Issue:6 Topics: Antineoplastic Agents; Blood Coagulation; Fibrinolytic Agents; Humans; Lenalidomide; Multiple Myelom	2008
Vascular complications of selected cancer therapies. Nature clinical practice. Cardiovascular medicine, 2008, Volume: 5, Issue:12 Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimet	2008
Pathogenesis and management of bleeding and thrombosis in plasma cell dyscrasias. British journal of haematology, 2009, Volume: 145, Issue:2 Topics: Blood Coagulation Disorders; Blood Platelet Disorders; Boronic Acids; Bortezomib; Hemorrhage; Humans	2009
Arterial thrombosis with immunomodulatory derivatives in the treatment of multiple myeloma: a single-center case series and review of the literature. Clinical lymphoma & myeloma, 2009, Volume: 9, Issue:4 Topics: Adult; Antineoplastic Agents; Arteries; Female; Humans; Immunosuppressive Agents; Middle Aged; Multi	2009
Thrombosis in multiple myeloma. Hematology. American Society of Hematology. Education Program, 2010, Volume: 2010 Topics: Humans; Lenalidomide; Multiple Myeloma; Risk Factors; Thalidomide; Thrombosis; Venous Thromboembolis	2010
[Thrombotic complications following the treatment of multiple myeloma with new agents]. Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2011, Volume: 31, Issue:186 Topics: Anthracyclines; Anticoagulants; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Dru	2011
Thrombosis in multiple myeloma (MM). Hematology (Amsterdam, Netherlands), 2012, Volume: 17 Suppl 1 Topics: Anthracyclines; Antineoplastic Agents, Hormonal; Dexamethasone; Humans; Immunologic Factors; Lenalid	2012
Underreporting of hemorrhagic and thrombotic complications of pharmaceuticals to the U.S. Food and Drug Administration: empirical findings for warfarin, clopidogrel, ticlopidine, and thalidomide from the Southern Network on Adverse Reactions (SONAR). Seminars in thrombosis and hemostasis, 2012, Volume: 38, Issue:8 Topics: Adverse Drug Reaction Reporting Systems; Clopidogrel; Hemorrhage; Humans; Thalidomide; Thrombosis; T	2012
[Left atrial thrombus in multiple myeloma treated with thalidomide]. Archives des maladies du coeur et des vaisseaux, 2003, Volume: 96, Issue:10 Topics: Aged; Female; Heart Atria; Heart Diseases; Humans; Multiple Myeloma; Thalidomide; Thrombosis	2003
Hepatocellular carcinoma with intra-atrial tumor thrombi. A report of three cases responsive to thalidomide treatment and literature review. Oncology, 2004, Volume: 67, Issue:3-4 Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Heart Atria; Humans; Liver Neoplasms	2004
Thalidomide and thrombosis. Clinical advances in hematology & oncology : H&O, 2003, Volume: 1, Issue:8 Topics: Angiogenesis Inhibitors; Drug Screening Assays, Antitumor; Heparin; Humans; Multiple Myeloma; Thalid	2003
[The revival of thalidomide: an old drug with new indications]. La Revue du praticien, 2006, Nov-30, Volume: 56, Issue:18 Topics: Angiogenesis Inhibitors; Drug Eruptions; Humans; Leprostatic Agents; Peripheral Nervous System Disea	2006
Thrombosis in multiple myeloma. Expert review of anticancer therapy, 2007, Volume: 7, Issue:3 Topics: Angiogenesis Inhibitors; Anticoagulants; Antineoplastic Agents; Blood Coagulation Factors; Cytokines	2007
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia, 2008, Volume: 22, Issue:2 Topics: Antineoplastic Agents; Aspirin; Heparin, Low-Molecular-Weight; Humans; International Normalized Rati	2008
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia, 2008, Volume: 22, Issue:2 Topics: Antineoplastic Agents; Aspirin; Heparin, Low-Molecular-Weight; Humans; International Normalized Rati	2008
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia, 2008, Volume: 22, Issue:2 Topics: Antineoplastic Agents; Aspirin; Heparin, Low-Molecular-Weight; Humans; International Normalized Rati	2008
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia, 2008, Volume: 22, Issue:2 Topics: Antineoplastic Agents; Aspirin; Heparin, Low-Molecular-Weight; Humans; International Normalized Rati	2008
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia, 2008, Volume: 22, Issue:2 Topics: Antineoplastic Agents; Aspirin; Heparin, Low-Molecular-Weight; Humans; International Normalized Rati	2008
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia, 2008, Volume: 22, Issue:2 Topics: Antineoplastic Agents; Aspirin; Heparin, Low-Molecular-Weight; Humans; International Normalized Rati	2008
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia, 2008, Volume: 22, Issue:2 Topics: Antineoplastic Agents; Aspirin; Heparin, Low-Molecular-Weight; Humans; International Normalized Rati	2008
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia, 2008, Volume: 22, Issue:2 Topics: Antineoplastic Agents; Aspirin; Heparin, Low-Molecular-Weight; Humans; International Normalized Rati	2008
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia, 2008, Volume: 22, Issue:2 Topics: Antineoplastic Agents; Aspirin; Heparin, Low-Molecular-Weight; Humans; International Normalized Rati	2008
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia, 2008, Volume: 22, Issue:2 Topics: Antineoplastic Agents; Aspirin; Heparin, Low-Molecular-Weight; Humans; International Normalized Rati	2008
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia, 2008, Volume: 22, Issue:2 Topics: Antineoplastic Agents; Aspirin; Heparin, Low-Molecular-Weight; Humans; International Normalized Rati	2008
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia, 2008, Volume: 22, Issue:2 Topics: Antineoplastic Agents; Aspirin; Heparin, Low-Molecular-Weight; Humans; International Normalized Rati	2008
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia, 2008, Volume: 22, Issue:2 Topics: Antineoplastic Agents; Aspirin; Heparin, Low-Molecular-Weight; Humans; International Normalized Rati	2008
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia, 2008, Volume: 22, Issue:2 Topics: Antineoplastic Agents; Aspirin; Heparin, Low-Molecular-Weight; Humans; International Normalized Rati	2008
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia, 2008, Volume: 22, Issue:2 Topics: Antineoplastic Agents; Aspirin; Heparin, Low-Molecular-Weight; Humans; International Normalized Rati	2008
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia, 2008, Volume: 22, Issue:2 Topics: Antineoplastic Agents; Aspirin; Heparin, Low-Molecular-Weight; Humans; International Normalized Rati	2008
Thalidomide in cancer. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2002, Volume: 56, Issue:1 Topics: Angiogenesis Inhibitors; Bradycardia; Exanthema; Humans; Interleukin-2; Interleukin-6; Neoplasms; Pe	2002

Article	Year
Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials. Blood, 2020, 08-27, Volume: 136, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; De	2020
Mature results of MM-011: a phase I/II trial of liposomal doxorubicin, vincristine, dexamethasone, and lenalidomide combination therapy followed by lenalidomide maintenance for relapsed/refractory multiple myeloma. American journal of hematology, 2014, Volume: 89, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Th	2014
Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance). Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Nov-01, Volume: 33, Issue:31 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Disease Pro	2015
Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance). Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Nov-01, Volume: 33, Issue:31 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Disease Pro	2015
Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance). Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Nov-01, Volume: 33, Issue:31 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Disease Pro	2015
Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance). Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Nov-01, Volume: 33, Issue:31 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Disease Pro	2015
Tailored thromboprophylaxis for patients with multiple myeloma treated by IMIDs. Leukemia & lymphoma, 2008, Volume: 49, Issue:8 Topics: Aspirin; Chemoprevention; Humans; Lenalidomide; Multiple Myeloma; Thalidomide; Thrombosis	2008
Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial. Journal of the National Cancer Institute, 2009, Aug-05, Volume: 101, Issue:15 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protoc	2009
Thalidomide-dexamethasone as up-front therapy for patients with newly diagnosed multiple myeloma: thrombophilic alterations, thrombotic complications, and thromboprophylaxis with low-dose warfarin. European journal of haematology, 2010, Volume: 84, Issue:6 Topics: Activated Protein C Resistance; Adult; Aged; Anticoagulants; Case-Control Studies; Dexamethasone; Fa	2010
Thalidomide and thrombosis in patients with multiple myeloma. Haematologica, 2001, Volume: 86, Issue:10 Topics: Aged; Antineoplastic Agents; Drug Synergism; Humans; Male; Middle Aged; Multiple Myeloma; Thalidomid	2001

Article	Year
Lenalidomide-associated arterial thrombosis in a patient with JAK2 positive atypical myeloproliferative neoplasm. BMJ case reports, 2017, Aug-11, Volume: 2017 Topics: Aged; Bone Marrow Neoplasms; Fatal Outcome; Female; Humans; Immunologic Factors; Janus Kinase 2; Len	2017
Risk factors, morbidity, and treatment of thrombosis in children and young adults with active inflammatory bowel disease. Journal of pediatric gastroenterology and nutrition, 2013, Volume: 57, Issue:3 Topics: Adolescent; Adult; Antibodies, Anticardiolipin; Anticoagulants; Catheterization; Catheters, Indwelli	2013
Increased PAC-1 expression among patients with multiple myeloma on concurrent thalidomide and warfarin. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2013, Volume: 24, Issue:8 Topics: Aged; Antibodies, Monoclonal; Anticoagulants; Blood Platelets; Female; Gene Expression; Humans; Immu	2013
[Hypercoagulable state in patients with multiple myeloma]. Zhongguo shi yan xue ye xue za zhi, 2015, Volume: 23, Issue:1 Topics: Blood Coagulation Tests; Fibrin Fibrinogen Degradation Products; Fibrinogen; Humans; Multiple Myelom	2015
Does the choice of thrombotic prophylactic drug depend on the known risk factors of patients with multiple myeloma in clinical practice? Thrombosis research, 2016, Volume: 143 Topics: Aged; Angiogenesis Inhibitors; Anticoagulants; Aspirin; Female; Heparin, Low-Molecular-Weight; Human	2016
Aspirin as thromboprophylaxis in myeloma. Leukemia & lymphoma, 2008, Volume: 49, Issue:8 Topics: Antineoplastic Combined Chemotherapy Protocols; Aspirin; Chemoprevention; Humans; Lenalidomide; Mult	2008
Novel agents in myeloma: an exciting saga. Cancer, 2009, Jan-15, Volume: 115, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Im	2009
Thalidomide-related vessel thrombosis in microsurgical free tissue transfer. Journal of reconstructive microsurgery, 2010, Volume: 26, Issue:3 Topics: Angiogenesis Inhibitors; Humans; Lymph Node Excision; Male; Mandibular Neoplasms; Microsurgery; Midd	2010
High incidence of arterial thrombosis in young patients treated for multiple myeloma: results of a prospective cohort study. Blood, 2010, Jul-08, Volume: 116, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Tri	2010
Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis. Seminars in thrombosis and hemostasis, 2011, Volume: 37, Issue:3 Topics: Activated Protein C Resistance; Aged; Anticoagulants; Aspirin; Boronic Acids; Bortezomib; Dexamethas	2011
[High-dose thalidomide for severe idiopathic obscure gastrointestinal bleeding in a patient at high-thrombotic risk]. Gastroenterologia y hepatologia, 2013, Volume: 36, Issue:1 Topics: Aged, 80 and over; Angiogenesis Inhibitors; Female; Gastrointestinal Hemorrhage; Humans; Risk Assess	2013
Thromboprophylaxis prescribing and thrombotic event rates in multiple myeloma patients treated with lenalidomide or thalidomide at a specialist cancer hospital. Asia-Pacific journal of clinical oncology, 2013, Volume: 9, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Anticoagulants; Aspirin; Cancer Care Facili	2013
[Classification of dermatologic manifestations in lupus erythematosus]. Annales de medecine interne, 2003, Volume: 154, Issue:1 Topics: Acitretin; Adrenal Cortex Hormones; Adult; Antimalarials; Clinical Trials as Topic; Dapsone; Dermato	2003
Thalidomide and thrombosis in multiple myeloma. Journal of thrombosis and haemostasis : JTH, 2003, Volume: 1, Issue:3 Topics: Humans; Multiple Myeloma; Risk; Thalidomide; Thrombosis; Treatment Outcome	2003
Thalidomide and thrombosis. Pathophysiology of haemostasis and thrombosis, 2003, Volume: 33 Suppl 1 Topics: Humans; Incidence; Neoplasms; Thalidomide; Thrombophilia; Thrombosis	2003
Thrombotic complications associated with thalidomide in multiple myeloma: an old problem with new questions and quandaries in decision-making. Thrombosis and haemostasis, 2004, Volume: 91, Issue:4 Topics: Aged; Decision Making; Female; Humans; Male; Middle Aged; Multiple Myeloma; Practice Guidelines as T	2004
Recombinant human erythropoietin and the risk of thrombosis in patients receiving thalidomide for multiple myeloma. Haematologica, 2004, Volume: 89, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Antineoplastic Agents; Drug Synergism; Erythropoieti	2004
Arterial thrombosis in four patients treated with thalidomide. Leukemia & lymphoma, 2005, Volume: 46, Issue:2 Topics: Aged; Arterial Occlusive Diseases; Aspirin; Drug Therapy, Combination; Female; Humans; Intracranial	2005
Should we screen patients for inherited thrombophilia before starting thalidomide? American journal of clinical oncology, 2006, Volume: 29, Issue:1 Topics: Administration, Oral; Aged; Antigens; Cerebral Infarction; Humans; Immunosuppressive Agents; Male; M	2006
Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis. Blood, 2006, Jul-01, Volume: 108, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Aspirin; Dexamethasone; Fibrinolytic Agents; Humans;	2006
Assessing the ability of the antiangiogenic and anticytokine agent thalidomide to modulate radiation-induced lung injury. International journal of radiation oncology, biology, physics, 2006, Oct-01, Volume: 66, Issue:2 Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Non-Small-Cell Lung; Female; Fibroblast	2006
Thrombomodulin levels are not modified during thalidomide treatment. European journal of haematology, 2006, Volume: 77, Issue:5 Topics: Female; Humans; Immunosuppressive Agents; Male; Multiple Myeloma; Thalidomide; Thrombomodulin; Throm	2006
Myeloma, thalidomide and thrombosis. Leukemia & lymphoma, 2006, Volume: 47, Issue:11 Topics: Humans; Multiple Myeloma; Thalidomide; Thrombosis	2006
Arterial thrombosis and thalidomide. Journal of thrombosis and thrombolysis, 2008, Volume: 25, Issue:2 Topics: Arteries; Humans; Male; Middle Aged; Multiple Myeloma; Thalidomide; Thrombosis	2008
Thrombosis of the corpora cavernosa complicating lenalidomide therapy of myelofibrosis. Leukemia research, 2008, Volume: 32, Issue:5 Topics: Aged; Humans; Lenalidomide; Male; Penis; Primary Myelofibrosis; Thalidomide; Thrombosis	2008
Prophylactic low-dose aspirin is effective antithrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma. Leukemia & lymphoma, 2007, Volume: 48, Issue:12 Topics: Adult; Aged; Antineoplastic Agents; Aspirin; Drug Therapy, Combination; Female; Heparin, Low-Molecul	2007
[Thalidomide and thrombosis]. Annales de dermatologie et de venereologie, 2000, Volume: 127, Issue:2 Topics: Adult; Dermatitis, Atopic; Female; Humans; Immunosuppressive Agents; Lupus Erythematosus, Cutaneous;	2000
[Thalidomide and thrombosis: three observations]. Presse medicale (Paris, France : 1983), 2001, Jun-09, Volume: 30, Issue:20 Topics: Adult; Aged; Behcet Syndrome; Histiocytosis, Langerhans-Cell; Humans; Immunosuppressive Agents; Lupu	2001
Warning: thalidomide-related thrombotic risk potentially concerns patients with lupus. Lupus, 2002, Volume: 11, Issue:2 Topics: Humans; Lupus Erythematosus, Cutaneous; Risk Assessment; Thalidomide; Thrombosis	2002
Endothelial dysfunction in antiangiogenesis-associated thrombosis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Jul-01, Volume: 20, Issue:13 Topics: Angiogenesis Inhibitors; Endothelium, Vascular; Humans; Neovascularization, Pathologic; Thalidomide;	2002
Early foetal thrombosis induced by thalidomide in mouse: possible explanation for teratogenicity. Experientia, 1977, Oct-15, Volume: 33, Issue:10 Topics: Animals; Extremities; Female; Fetal Diseases; Hemorrhage; Mice; Mice, Inbred C57BL; Pregnancy; Thali	1977

thalidomide and Blood Clot